Sponsor:
Gerald Maguire, MD
Code:
NCT02909088
Conditions
Stuttering, Adult
Childhood-onset Fluency Disorder
Speech Disorders
Language Disorders
Communication Disorder
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ecopipam 50mg
Ecopipam 100mg
Brief summary:
Conditions
Stuttering, Adult
Childhood-onset Fluency Disorder
Speech Disorders
Language Disorders
Communication Disorder
Study ID
NCT02909088
Start date
Sep, 2016
Status verified date
Oct, 2016
Completion date
Nov, 2017
Anticipated
Primary completion date
Aug, 2017
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Not accepted
Enrollment
10 participants
Anticipated
Allocation
Non randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Ecopipam 50mg
experimental: Ecopipam 100mg
Interventions
Ecopipam 50mg
Ecopipam 100mg
Primary outcome measure
Locations
CITrials
Recruiting
Riverside, California, United States, 92506
Contacts
Sponsor
Gerald Maguire, MD
Last update posted
Oct 26, 2016
Last verified
Oct, 2016
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Gerald Maguire, MD on 2016-10-26.